Clinical Scorecard: BVI Introduces Virtuoso at Euretina
At a Glance
| Category | Detail |
|---|---|
| Condition | Cataract and vitreoretinal procedures |
| Key Mechanisms | Advanced fluidics control, ultrasound delivery, aspiration performance |
| Target Population | Patients requiring cataract and vitreoretinal surgery |
| Care Setting | Surgical settings, specifically during cataract and vitreoretinal procedures |
Key Highlights
- Dual-function phaco-vitrectomy device
- Showcased at the 2025 EURetina Congress
- Data on post-occlusion break surge and energy delivery consistency
- Currently undergoing premarket clinical investigation
- Not yet received regulatory clearance (CE mark or FDA 510(k))
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
- Device has not received regulatory clearance
Patient & Prescribing Data
Patients undergoing cataract and vitreoretinal surgeries
Integration of multiple surgical functions into a single platform
Clinical Best Practices
- Monitor for regulatory updates regarding Virtuoso
- Evaluate clinical data from ongoing investigations
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.